- Details
- Alicia Morgans engages with Mercedes Mitjavila to discuss the promising advancements in the use of imaging, particularly PSMA PET technology, in advanced prostate cancer care. Dr. Mitjavila highlights that this imaging technology allows for highly sensitive and specific disease localization, thereby potentially altering disease stratification and treatment plans. She emphasizes its greatest utilit...
|
- Details
- Alicia Morgans converses with Enrique Gonzalez-Billalabeitia about the crucial role of molecular testing in managing prostate cancer. Dr. Gonzalez-Billalabeitia emphasizes that molecular testing helps in identifying effective treatments and potential germline mutations that could benefit not only the patient but also their family. In his practice in Spain, the testing is performed as early as poss...
|
- Details
- Alicia Morgans and Xavier Maldonado discuss the topic of bladder preservation in the treatment of muscle invasive bladder cancer. Dr. Maldonado shares the data presented at ASTRO, highlighting that bladder preservation, while suitable for very specific patients, has comparable metastasis-free survival rates to cystectomy. He mentions that prognostic factors such as tumor size, absence of multiple...
|
- Details
- Claudia Ungarelli discusses the importance of patient engagement in cancer care. She references a study revealing an overall survival advantage for cancer patients who had access to a monitoring and reporting system for therapy side effects, indicating that such patient engagement could be as beneficial as a new drug therapy. ANTURE, formed in 2020 from a Facebook group for kidney cancer patients,...
|
- Details
- Edoardo Fiorini reflects on the decade-long journey of PaLiNUro, an Italian patient advocacy association for bladder cancer, inspired by the American BCAN and initiated by Andrea Necchi. A founding member of the World Bladder Cancer Patient Coalition, PaLiNUro fosters cooperation between doctors and patients, providing comfort, sharing information, promoting patient rights, and enhancing life qual...
|
- Details
- Alicia Morgans engages with Miguel Ángel Climent Durán about bone health in prostate cancer. Dr. Climent Durán highlights the significance of differing considerations for patients with castration-resistant and hormone-sensitive prostate cancer. For the former, it's essential to prevent future bone events such as fractures, and for the latter, managing osteoporosis caused by hormonal treatments is...
|
- Details
- Charles Ryan and Ignacio Pelaez discuss the complexities of second-line kidney cancer treatments. Dr. Pelaez explains that the choice of second-line treatment largely depends on the first-line therapies used. Historically, tyrosine kinase inhibitors (TKIs) in monotherapy have been the preferred option in Spain. The robust data supporting second-line treatment options include another TKI or monothe...
|
- Details
- Alicia Morgans speaks with Joaquim Bellmunt about advances in urothelial carcinoma. Dr. Bellmunt outlines the progress and challenges in targeted therapies, such as PARP inhibitors, antibody drug conjugates, and immunotherapy checkpoint inhibitors. Despite some negative trials, there are exciting prospects on the horizon. He discusses promising therapies like antibody drug conjugates targeting HER...
|
- Details
- Charles Ryan and Cristina Suarez discuss the importance and relevance of the Spanish Oncology Genito Urinary Group (SOGUG) conference. The conference brings together a variety of specialists including oncologists, urologists, radiation oncologists, and pathologists, fostering a high-level discourse on urologic cancer. In 2022, the congress boasts 44 speakers and has been positively received. Dr. S...
|
- Details
- President and Vice President of the SOGUG (Spanish Oncology Genito Urinary Group), Cristina Suarez and Aránzazu González del Alba join Charles Ryan in a discussion on the SOGUG's upcoming annual meeting being held November 16-18 in Madrid, Spain. Founded in 1998 and with more than 500 members, the majority from the field of Medical Oncology, the Spanish Genitourinary Oncology Group, is a non-profi...
|
